Dr. Becerra on Sequencing Therapies in Pancreatic Cancer

Carlos Becerra, MD
Published: Monday, Aug 27, 2018



Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses sequencing therapies in the treatment of patients with pancreatic cancer.

Currently, physicians do not have a head-to-head comparison between the different therapeutic agents. Therefore, in younger patients with a robust performance status there is a trend to treat patients with FOLFIRINOX, which is a 3-drug combination regimen, explains Becerra.

In older patients who are not as robust, there is a tendency to treat them with gemcitabine and nab-paclitaxel (Abraxane) first. Upon disease progression, physicians can switch to an alternative regimen. If a physician starts with gemcitabine and nab-paclitaxel and the patient's tumor gets worse, they can consider adding or changing to either FOLFIRINOX if the patient still has a very good performance status, or a variation such as FOLFOX, says Becerra. Another regimen that can be utilized is liposomal irinotecan in combination with 5-fluorouracil, which is approved as second-line chemotherapy in this particular setting, states Becerra.


Carlos Becerra, MD, medical oncologist, Texas Oncology, discusses sequencing therapies in the treatment of patients with pancreatic cancer.

Currently, physicians do not have a head-to-head comparison between the different therapeutic agents. Therefore, in younger patients with a robust performance status there is a trend to treat patients with FOLFIRINOX, which is a 3-drug combination regimen, explains Becerra.

In older patients who are not as robust, there is a tendency to treat them with gemcitabine and nab-paclitaxel (Abraxane) first. Upon disease progression, physicians can switch to an alternative regimen. If a physician starts with gemcitabine and nab-paclitaxel and the patient's tumor gets worse, they can consider adding or changing to either FOLFIRINOX if the patient still has a very good performance status, or a variation such as FOLFOX, says Becerra. Another regimen that can be utilized is liposomal irinotecan in combination with 5-fluorouracil, which is approved as second-line chemotherapy in this particular setting, states Becerra.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Medical Crossfire®: Navigating Treatment Decisions in Pancreatic Cancer: Key QuestionsJun 29, 20191.5
Publication Bottom Border
Border Publication
x